

Prescribing Information: STAMARIL® Powder and solvent for suspension for injection in a pre-filled syringe.

Yellow fever vaccine (Live)

Please refer to Summary of Product Characteristics for full product information before prescribing

Presentation: One dose (0.5mL) of the reconstituted vaccine contains the live, attenuated 17D-204 strain of the yellow fever virus, not less than 1000 IU.

Indication: Active immunisation against yellow fever in adults and children aged ≥9 months, for persons travelling to, passing through or living in an area where there is a current or periodic risk of yellow fever transmission. Travelling to any country that requires an International Certificate of Vaccination for entry (which may or may not depend on the previous itinerary). Handling potentially infectious materials (e.g. laboratory personnel). For updated yellow fever vaccination requirements and recommendations consult the WHO dedicated website or refer to resources provided by national health authorities.

Dosage and Administration: STAMARIL® is to be used on the basis of official recommendations. Adults and children aged 9 months and over: A single dose of 0.5 mL of reconstituted vaccine. In older people the dose is the same as for adults. However due to a potentially higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a significant and unavoidable risk of acquiring yellow fever infection such as travel to an area where there is current or periodic risk of yellow fever transmission. The vaccine must not be given to children less than 6 months old. Vaccination against yellow fever is not recommended in children aged from 6 months up to 9 months except in specific circumstances and in accordance with available official recommendations, in which case the dose is the same as in children aged 9 months and older. The vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed. The duration of protection following administration of one single 0.5 mL dose of STAMARIL is expected to be at least 10 years and may be life-long. In accordance with WHO advice and International Health Regulations, the validity of a certificate of vaccination against yellow fever shall extend for the life of the person vaccinated. However, re-vaccination with one dose of 0.5 mL may be needed in individuals who had an insufficient immune response after their primary vaccination if they continue to be at risk for yellow fever virus infection. Re-vaccination may also be required, depending on official recommendations of local Health Authorities. It is preferable to give the reconstituted vaccine by subcutaneous injection. Intramuscular injection may be performed if this is in accordance with applicable official recommendations. For intramuscular use, the recommended injection sites are the anterolateral aspect of the thigh in children less than 12 months of age, the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in children 12 months through 35 months of age or the deltoid muscle in children from 36 months of age onwards and adults. Do not inject intravascularly. Intramuscular injection can cause injection site haematoma; STAMARIL® should not be given by the intramuscular route to persons with any bleeding disorder, such as haemophilia or thrombocytopenia, or to persons on anticoagulant

therapy. The subcutaneous route of administration should be used instead.

Special Populations: *Paediatric population:* Children aged from 6 months up to 9 months should only be vaccinated under special circumstances (e.g. during major outbreaks) and on the basis of current official advice. *Older people:* Persons aged 60 years and older may have an increased risk of serious and potentially fatal adverse reactions when compared to other age groups. Therefore, the vaccine should only be given to those who are visiting areas where there is an ongoing risk of yellow fever transmission at the time of travel. Countries designated by WHO as where vaccination is not generally recommended, or not recommended, should be considered as not representing a significant and unavoidable risk (refer to updated WHO list of countries with risk of yellow fever transmission). *HIV infection:* STAMARIL® must not be administered to persons with symptomatic HIV infection or with asymptomatic HIV infection when accompanied by evidence of impaired immune function. Official guidance should be taken into account when considering the risks and benefits of vaccinating an asymptomatic HIV-infected person who cannot avoid travel to an endemic area. Children aged at least 6 months born to HIV positive mothers may be vaccinated if it is confirmed that they are not infected with HIV. HIV infected children aged at least 6 months who are potentially in need of protection against yellow fever should be referred to a specialist paediatric team for advice on whether or not to vaccinate. *Pregnancy:* The potential risk of administration of STAMARIL® during pregnancy is unknown. As STAMARIL® is a live attenuated vaccine, it should not be given during pregnancy unless when clearly needed and only after careful consideration of the potential risks and benefits. Pregnancy should be avoided for one month following vaccination. *Breastfeeding:* Due to risk of transmission of the vaccine virus strain to the infants from breastfeeding mothers, STAMARIL® should not be given to nursing mothers unless when clearly needed such as during an outbreak and only if the potential benefits to the mother outweigh the potential risks, including those to the breastfed child. In case vaccination is needed, it is recommended to interrupt breast-feeding for at least 2 weeks following vaccination.

Contraindications: Please refer to sections 4.3 and 4.4 of the STAMARIL summary of product characteristics for further details about contraindications to STAMARIL. Hypersensitivity reactions to eggs, chicken proteins or any component of STAMARIL®; severe hypersensitivity reaction to any yellow fever vaccine; immunosuppression (congenital or acquired, includes individuals receiving immunosuppressive therapies such as treatment with high-dose systemic corticosteroids, any other medicinal products including biologicals with known immunosuppressive properties, radiotherapy, cytotoxic drugs or any other condition which may result in immunocompromised status); history of thymus dysfunction (including *myasthenia gravis*, thymoma); thymectomy (for any reason); symptomatic HIV infection; asymptomatic HIV infection when accompanied by evidence of impaired immune function; moderate or

severe febrile illness or acute illness. Age less than 6 months.

Precautions and Warnings: As with any vaccine, vaccination with STAMARIL may not protect 100% of vaccinated individuals. Appropriate treatment and supervision should be readily available in case of anaphylaxis or other severe hypersensitivity reaction following vaccine administration. Yellow fever vaccine should only be given to persons who are/ will be at risk of infection or in cases to comply with International Health Regulations. Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from faints and manage syncopal reactions. The tip caps of the prefilled syringes contain a natural rubber latex derivative, which may cause allergic reactions in latex sensitive individuals. STAMARIL contains less than 1 mmol sodium (23 mg) per dose that is to say essentially "sodium free". STAMARIL contains less than 1 mmol potassium (39 mg) per dose that is to say essentially "potassium free". STAMARIL contains approximately 8 mg of sorbitol (E420) per dose.

Adverse Reactions: *Very common side effects in general population:* headache, myalgia, asthenia and injection site pain/tenderness. *Very common side effects specific to the paediatric population include:* Appetite loss, drowsiness, irritability, and crying. Pyrexia and vomiting are very common in toddlers. *Common side effects in general population:* Arthralgia, nausea, rash, injection site reactions (erythema/redness, haematoma, induration, oedema/swelling), vomiting and pyrexia. *Uncommon side effects:* Dizziness, abdominal pain, pruritis, and injection-site papule. *Rare/very rare side effects:* YEL-AVD, YEL-AND, seizure, meningitis aseptic, diarrhoea, rhinitis. *Frequency not known:* Anaphylactoid reaction including angioedema, paraesthesia, urticaria, influenza-like illness. Post-marketing studies have reported serious adverse events including severe hypersensitivity or anaphylactic reactions, Yellow-fever vaccine associated neurotropic disease (YEL-AND) and Yellow fever vaccine-associated viscerotropic disease (YEL-AVD). There are some reported cases of YEL-AND and YEL-AVD with a fatal outcome. Cases of YEL-AND have been reported to occur within 30 days following vaccination and may manifest as either encephalitis (with or without demyelination), or as a neurologic disease with peripheral nervous system involvement (e.g. Guillain-Barré syndrome). Encephalitis usually starts with high fever with headache that may progress to include encephalopathy (e.g. confusion, lethargy, personality change lasting more than 24 hours), focal neurologic deficits, cerebellar dysfunction or seizures. YEL-AND with peripheral nervous system involvement usually

manifests as bilateral limb weakness or peripheral cranial nerve paresis with decreased or absent tendon reflexes. YEL-AVD have been reported with onset of signs and symptoms within 10 days after vaccination in majority of cases reported. They may include pyrexia, fatigue, myalgia, headache and hypotension progressing to liver dysfunction with jaundice, muscle cytolysis, thrombocytopenia, and acute respiratory and renal failure. For YEL-AND, the risk appears higher in those aged over 60 years and below 9 months of age. Congenital or acquired immunodeficiency has also been recognised as a predisposing condition. For YEL-AVD, risk appears higher in those aged over 60 years. Medical history of thymus dysfunction or thymectomy are predisposing conditions for YEL-AVD. Vaccinees should be instructed to seek medical attention if they experience any symptoms suggestive of YEL-AND or YEL-AVD, and should also be reminded to inform their healthcare professional that they received yellow fever vaccine.

Interactions: STAMARIL must not be mixed with any other vaccine or medicinal product in the same syringe. If there is a need to administer another injectable vaccine(s) at the same time as STAMARIL each vaccine should be injected into a separate site (and preferably a separate limb). This vaccine may be administered at the same time as measles vaccine if this is in accordance with official recommendations. It may be administered at the same time as vaccines containing typhoid Vi capsular polysaccharide and/or inactivated hepatitis A virus. It must not be administered to persons who are receiving immunosuppressive therapies, high-dose systemic corticosteroids (e.g. daily dose of 20 mg or 2 mg/kg body weight of prednisone or equivalent for 2 weeks or more or daily dose of 40 mg or more of prednisone for more than one week), any other medicinal products including biologicals with known immunosuppressive properties, radiotherapy, cytotoxic drugs or any other condition which may result in immunocompromised status. It can induce false positive results with laboratory and/or diagnostic tests for other flavivirus related diseases such as dengue or Japanese encephalitis.

List price: Single pack containing vial of lyophilised powder with 0.5 millilitre diluent in a syringe with 2 separate needles. Basic NHS cost £39.72

Legal Category: POM

Marketing Authorisation Number: PL 46602/0007

Marketing Authorisation Holder: Sanofi Pasteur Europe, 14 Espace Henry Vallée, 69007 Lyon, France

Further information is available from: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Date of preparation: February 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com

CERTIFICATE FOR PROMOTIONAL ITEMS (PMCPA)

Version: 1 . 0

Document Number: MAT-GB-2100120

Document Name: Stamaril PI UK February 2021

Country: United Kingdom

Product: Stamaril

Material Type: (Abbreviated) Product Information / ISI

Material Intent: Promotional

Certification Type: Certification

Audience: Healthcare Professionals

Additional Audience:

Intended Use: External Use

Method of Dissemination: By Sales, Digital, Print

Material Owner: Emine Anandam

I have examined the final form of the material and in my belief it is in accordance with the requirements of the relevant regulations relating to advertising and this Code, is not inconsistent with the marketing authorization and the summary of product characteristics, and is a fair and truthful presentation of the facts about the medicine.

Role	Signature
Natalya Vassilouthis - Medical	Date: 17-Feb-2021 09:55:15 GMT+0000